Cargando…
Natural History and Management of Intraductal Papillary Mucinous Neoplasms: Current Evidence
BACKGROUND: With the use of modern cross-sectional abdominal imaging modalities, an increasing number of cystic pancreatic lesions are identified incidentally. Although there is no pathological diagnosis available in most cases, it is believed that the majority of these lesions display small branch-...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger Verlag für Medizin und Naturwissenschaften GmbH
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433132/ https://www.ncbi.nlm.nih.gov/pubmed/26288612 http://dx.doi.org/10.1159/000375186 |
_version_ | 1782371590544031744 |
---|---|
author | Fritz, Stefan Lerch, Markus M. |
author_facet | Fritz, Stefan Lerch, Markus M. |
author_sort | Fritz, Stefan |
collection | PubMed |
description | BACKGROUND: With the use of modern cross-sectional abdominal imaging modalities, an increasing number of cystic pancreatic lesions are identified incidentally. Although there is no pathological diagnosis available in most cases, it is believed that the majority of these lesions display small branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) of the pancreas. Even though a number of large clinical series have been published, many uncertainties remain with regard to this entity of mucinous cystic neoplasms. METHODS: Systematic literature review. RESULTS: Main-duct (MD) and mixed-type IPMNs harbor a high risk of malignant transformation. It is conceivable that most IPMNs with involvement of the main duct tend to progress to invasive carcinoma over time. Thus, formal oncologic resection is the treatment of choice in surgically fit patients. In contrast, the data regarding BD-IPMN remain equivocal, resulting in conflicting concepts. To date, it is not clear whether and which BD-IPMNs progress to carcinoma and how long this progression takes. CONCLUSION: While patients with MD-IPMNs should undergo surgical resection if comorbidities and life expectancy permit this, the management of small BD-IPMNs remains controversial. Population-based studies with long-term follow-up are needed to define which cohort of patients can be observed safely without immediate resection. |
format | Online Article Text |
id | pubmed-4433132 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | S. Karger Verlag für Medizin und Naturwissenschaften GmbH |
record_format | MEDLINE/PubMed |
spelling | pubmed-44331322016-02-01 Natural History and Management of Intraductal Papillary Mucinous Neoplasms: Current Evidence Fritz, Stefan Lerch, Markus M. Viszeralmedizin Review Article BACKGROUND: With the use of modern cross-sectional abdominal imaging modalities, an increasing number of cystic pancreatic lesions are identified incidentally. Although there is no pathological diagnosis available in most cases, it is believed that the majority of these lesions display small branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) of the pancreas. Even though a number of large clinical series have been published, many uncertainties remain with regard to this entity of mucinous cystic neoplasms. METHODS: Systematic literature review. RESULTS: Main-duct (MD) and mixed-type IPMNs harbor a high risk of malignant transformation. It is conceivable that most IPMNs with involvement of the main duct tend to progress to invasive carcinoma over time. Thus, formal oncologic resection is the treatment of choice in surgically fit patients. In contrast, the data regarding BD-IPMN remain equivocal, resulting in conflicting concepts. To date, it is not clear whether and which BD-IPMNs progress to carcinoma and how long this progression takes. CONCLUSION: While patients with MD-IPMNs should undergo surgical resection if comorbidities and life expectancy permit this, the management of small BD-IPMNs remains controversial. Population-based studies with long-term follow-up are needed to define which cohort of patients can be observed safely without immediate resection. S. Karger Verlag für Medizin und Naturwissenschaften GmbH 2015-02 2015-02-09 /pmc/articles/PMC4433132/ /pubmed/26288612 http://dx.doi.org/10.1159/000375186 Text en Copyright © 2015 by S. Karger GmbH, Freiburg |
spellingShingle | Review Article Fritz, Stefan Lerch, Markus M. Natural History and Management of Intraductal Papillary Mucinous Neoplasms: Current Evidence |
title | Natural History and Management of Intraductal Papillary Mucinous Neoplasms: Current Evidence |
title_full | Natural History and Management of Intraductal Papillary Mucinous Neoplasms: Current Evidence |
title_fullStr | Natural History and Management of Intraductal Papillary Mucinous Neoplasms: Current Evidence |
title_full_unstemmed | Natural History and Management of Intraductal Papillary Mucinous Neoplasms: Current Evidence |
title_short | Natural History and Management of Intraductal Papillary Mucinous Neoplasms: Current Evidence |
title_sort | natural history and management of intraductal papillary mucinous neoplasms: current evidence |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433132/ https://www.ncbi.nlm.nih.gov/pubmed/26288612 http://dx.doi.org/10.1159/000375186 |
work_keys_str_mv | AT fritzstefan naturalhistoryandmanagementofintraductalpapillarymucinousneoplasmscurrentevidence AT lerchmarkusm naturalhistoryandmanagementofintraductalpapillarymucinousneoplasmscurrentevidence |